What is the 13F Pro Quality Score for STE?

13F Pro ranks STERIS plc (STE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View STE's current score at https://13fpro.ai/company/STE (free sign-up required for the full ranking).

Which hedge funds own the most STE stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of STE include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/STE as soon as new 13F filings post.

Where does 13F Pro source STE data?

All STERIS plc fundamentals and ownership data come directly from SEC EDGAR. STERIS plc files with the SEC under CIK 1757898. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is STE in?

STERIS plc (STE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives STE's revenue?

Per STERIS plc's latest 10-Q filed with the SEC on 2026-08-07, the biggest revenue drivers are: Healthcare segment ($1,048.3M, +7.6% YoY); Applied Sterilization Technologies (AST) ($297.6M, +5.8% YoY); Life Sciences segment ($146.7M, +8.6% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/STE.

What are STE's largest expenses?

STERIS plc's latest 10-Q reports these as the largest expense items: Cost of revenues ($808.6M, +5.9% YoY); Selling, general, and administrative ($369.7M, +4.5% YoY); Research and development ($28.6M, +8.5% YoY). Sourced directly from SEC EDGAR filing text for Q1 FY2027 (quarter ended June 30, 2026).

How often is STE research updated on 13F Pro?

STE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

STERIS plc(STE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSElarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 1757898 STE stock profile & AI dashboard →

InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro Quality Score

68.2/100

Rank #326 of 2,961 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why STE Scores 68/100

exact factor attribution · 2026-09-11

STE's composite is driven by scale and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Scale

+4.4 pts

80th pct

Profitability

+3.3 pts

72th pct

Capital efficiency

+2.9 pts

79th pct

Earnings quality

+2.7 pts

77th pct

Free cash flow

+2.4 pts

66th pct

Earnings growth

+1.7 pts

85th pct

Institutional flow

+0.3 pts

56th pct

Revenue growth

+0.3 pts

52th pct

Shareholder dilution

+0.2 pts

54th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

STE Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for STERIS plc (STE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores STE at 68.2/100 on a 32-signal composite quality model, placing it at rank #326 of 2,961 stocks — the top 25% of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), STERIS plc reports quarterly revenue of $1.5B, net income of $200.1M, an operating margin of 19.1%. Top institutional holders of STE by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. STE trades on the NYSE exchange and files with the SEC under CIK 1757898. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate STE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for STERIS plc directly from SEC EDGAR. STERIS plc's 13F Pro composite quality score has ranged between 68 and 72 since 2026, currently 68.2 — a stable long-term trajectory across 48 quarterly and live scoring snapshots.

What's Driving STE's Business? Latest 10-Q Breakdown

AI-extracted from STERIS plc's 10-Q filed 2026-08-07 — Q1 FY2027 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Biggest Revenue Drivers

Healthcare segment$1,048.3M+7.6% YoY

Growth in service (+9.6%), consumable (+9.2%), and capital equipment (+1.4%) driven by increased volume and pricing.

Applied Sterilization Technologies (AST)$297.6M+5.8% YoY

Constant currency organic growth of 4.7% primarily from increased pricing, partially offset by volume decline.

Biggest Revenue Drivers

Total revenue: $1,492.7M+7.3% YoY

Healthcare segment$1,048.3M+7.6% YoY

Growth in service (+9.6%), consumable (+9.2%), and capital equipment (+1.4%) driven by increased volume and pricing.

Applied Sterilization Technologies (AST)$297.6M+5.8% YoY

Constant currency organic growth of 4.7% primarily from increased pricing, partially offset by volume decline.

Life Sciences segment$146.7M+8.6% YoY

Growth in capital equipment (+17.4%), consumable (+8.2%), and service (+2.4%) driven by increased volume and pricing.

Largest Expense Items

Cost of revenues$808.6M+5.9% YoY

Increase driven by higher volume and inflation, partially offset by favorable pricing and productivity.

Selling, general, and administrative$369.7M+4.5% YoY

Increase attributable to higher compensation and benefit costs and marketing/sales spending, offset by favorable FX and lower bad debt.

Research and development$28.6M+8.5% YoY

Continued investment focused on sterile processing, procedural products, and gastrointestinal endoscopy device capabilities.

Margins: Gross profit margin expanded 70 basis points to 45.8%, driven by favorable pricing (100 bps), productivity (40 bps), and mix (40 bps), partially offset by inflation (60 bps) and adjustments (50 bps). Operating margin improved on higher volumes and operational efficiency.

Watch Items from the Filing

New restructuring plan announced post-quarter (Aug 5, 2026) expects $55M–$70M in total charges, with completion targeted in FY2030, impacting Chemistry manufacturing consolidation.
IRS dispute regarding deemed dividend inclusions and withholding tax for FY2018; potential liability of $50M (excluding interest/penalties); case pending in U.S. Tax Court.
Illinois EO litigation settlement obligations of $48.2M accrued in FY2025; substantially all payments made by July 31, 2026, with claims administration largely completed.
AST segment operating margin declined 60 bps to 48.0% due to higher depreciation, lower productivity, and labor inflation outweighing pricing gains.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$1.5B

Net Income

Q2 2026

$200.1M

Free Cash Flow

Q2 2026

$279.6M

Operating Margin

Q2 2026

19.1%

ROIC

Q2 2026

12.6%

D/E Ratio

Q2 2026

0.26

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+8.7% YoY

$5.94BFY 2026

FY23 $4.54BFY24 $5.14BFY25 $5.46BFY26 $5.94B

Net Income

+27.3% YoY

$782.3MFY 2026

FY23 $107.0MFY24 $378.2MFY25 $614.6MFY26 $782.3M

Operating Income

+27.1% YoY

$1.10BFY 2026

FY23 $791.1MFY24 $836.1MFY25 $866.6MFY26 $1.10B

EPS (Diluted)

+27.9% YoY

$7.93FY 2026

FY23 $1.07FY24 $3.81FY25 $6.20FY26 $7.93

Total Assets

+5.8% YoY

$10.74BFY 2026

FY23 $10.82BFY24 $11.06BFY25 $10.15BFY26 $10.74B

Total Debt

-5.5% YoY

$1.93BFY 2026

FY23 $3.08BFY24 $3.21BFY25 $2.04BFY26 $1.93B

Op. Cash Flow

+16.8% YoY

$1.34BFY 2026

FY23 $756.9MFY24 $973.3MFY25 $1.15BFY26 $1.34B

Free Cash Flow

+25.0% YoY

$972.4MFY 2026

FY23 $395.0MFY24 $613.0MFY25 $778.0MFY26 $972.4M

Metric	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$5.94B +8.7%	$5.46B +6.2%	$5.14B +13.3%	$4.54B +7.4%	$4.22B +35.9%	$3.11B
Net Income	$782.3M +27.3%	$614.6M +62.5%	$378.2M +253.4%	$107.0M -56.1%	$243.9M -38.6%	$397.4M
Operating Income	$1.10B +27.1%	$866.6M +3.6%	$836.1M +5.7%	$791.1M +65.6%	$477.8M -12.9%	$548.4M
EPS (Diluted)	$7.93 +27.9%	$6.20 +62.7%	$3.81 +256.1%	$1.07 -56.9%	$2.48 -46.4%	$4.63
Total Assets	$10.74B +5.8%	$10.15B -8.3%	$11.06B +2.2%	$10.82B -5.3%	$11.42B +73.8%	$6.57B
Total Debt	$1.93B -5.5%	$2.04B -36.3%	$3.21B +4.1%	$3.08B -0.3%	$3.09B +87.1%	$1.65B
Operating Cash Flow	$1.34B +16.8%	$1.15B +18.0%	$973.3M +28.6%	$756.9M +10.5%	$684.8M -0.7%	$689.6M
Free Cash Flow	$972.4M +25.0%	$778.0M +26.9%	$613.0M +55.2%	$395.0M -0.6%	$397.2M -11.8%	$450.4M

Get alerted when STE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for STERIS plc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of STE

BlackRock, Inc.
$1.9B8,820,889 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.3B6,406,906 sh
STATE STREET CORP
$1.1B5,072,818 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$1.1B5,001,950 sh
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
$850.4M3,801,077 sh
MORGAN STANLEY
$831.8M3,950,067 sh
WELLINGTON MANAGEMENT GROUP LLP
$737.6M3,502,897 sh
Orbis Allan Gray Ltd
$563.8M2,677,710 sh
GEODE CAPITAL MANAGEMENT, LLC
$548.6M2,615,842 sh
GENERATION INVESTMENT MANAGEMENT LLP
$480.2M2,280,698 sh

Fund	Value	Shares
BlackRock, Inc.	$1.9B	8,820,889
VANGUARD CAPITAL MANAGEMENT LLC	$1.3B	6,406,906
STATE STREET CORP	$1.1B	5,072,818
VANGUARD PORTFOLIO MANAGEMENT LLC	$1.1B	5,001,950
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	$850.4M	3,801,077
MORGAN STANLEY	$831.8M	3,950,067
WELLINGTON MANAGEMENT GROUP LLP	$737.6M	3,502,897
Orbis Allan Gray Ltd	$563.8M	2,677,710
GEODE CAPITAL MANAGEMENT, LLC	$548.6M	2,615,842
GENERATION INVESTMENT MANAGEMENT LLP	$480.2M	2,280,698

Companies Similar to STE

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

BSX

BOSTON SCIENTIFIC CORP

AI score

Very similar · 25 shared holders

VOLORIDGE INVESTMENT MANAGEMENT, LLC Clearbridge Investments, LLC PFA Pension, Forsikringsaktieselskab

IDXX

IDEXX LABORATORIES INC /DE

AI score

Very similar · 26 shared holders

Williams Jones Wealth Management, LLC.Life Cycle Investment Partners Ltd Clearbridge Investments, LLC

MDT

Medtronic plc

AI score

Very similar · 25 shared holders

Boston Partners WORLDQUANT MILLENNIUM ADVISORS LLC Swedbank AB

LABCORP HOLDINGS INC.

AI score

Very similar · 25 shared holders

Select Equity Group, L.P.Boston Partners AVIVA PLC

WST

WEST PHARMACEUTICAL SERVICES INC

AI score

Very similar · 30 shared holders

GENERATION INVESTMENT MANAGEMENT LLP Findlay Park Partners LLP ROYAL LONDON ASSET MANAGEMENT LTD

DGX

QUEST DIAGNOSTICS INC

AI score

Very similar · 26 shared holders

Boston Partners PFA Pension, Forsikringsaktieselskab Copeland Capital Management, LLC

RMD

RESMED INC

AI score

Very similar · 32 shared holders

WORLDQUANT MILLENNIUM ADVISORS LLC VOLORIDGE INVESTMENT MANAGEMENT, LLC Life Cycle Investment Partners Ltd

IQV

IQVIA HOLDINGS INC.

AI score

Very similar · 25 shared holders

Boston Partners Orbis Allan Gray Ltd SEB Asset Management AB

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put STE on your watchlist

Track score changes the day STERIS plc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is STE a good stock to buy?

13F Pro's AI-powered analysis of STERIS plc (STE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for STE are available on the STE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. STE is classified as a large company.

Which hedge funds own STE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling STE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of STERIS plc's investment landscape.